Navelbine Oral (Vinorelbine)

Vinorelbine interferes with microtubule dynamics by binding to tubulin, preventing polymerisation. This blocks the formation of the mitotic spindle, arrests cancer cells in the M phase of mitosis, and ultimately leads to programmed cell death (apoptosis).

The dosage of Navelbine Oral is individualized by the prescribing oncologist based on factors such as cancer type, disease stage, patient weight, renal and hepatic function, and prior treatment history. Only a qualified healthcare professional should determine the appropriate regimen.

Vinorelbine is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception. Safety during breastfeeding has not been established, and nursing mothers are generally advised to avoid the drug.

To request Navelbine Oral, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Navelbine Oral offers the same active ingredient as the intravenous formulation but provides the convenience of oral administration, eliminating the need for infusion centers. Pharmacokinetic exposure is comparable when dose adjustments are made, though clinicians may monitor blood counts more closely due to oral absorption variability.

Store Navelbine Oral tablets at ambient temperature, below 25 °C, in the original blister pack. Protect them from moisture, heat, and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged.

Navelbine Oral tablets are taken by mouth with water, usually on an empty stomach as directed by the oncologist. The exact timing relative to meals and other medications is determined by the treatment protocol to optimise absorption and minimise gastrointestinal side effects.

The most serious risks include severe neutropenia leading to infection, pulmonary toxicity such as interstitial pneumonitis, and rare but life‑threatening hypersensitivity reactions. Patients should be monitored closely for signs of infection, respiratory difficulty, or allergic symptoms.

Navelbine Oral is contraindicated in patients with known hypersensitivity to vinorelbine or other Vinca alkaloids, in pregnant women, and in individuals with severe hepatic impairment. Caution is also advised for patients with pre‑existing bone‑marrow suppression or uncontrolled infections.